Antibodies
29 December 2023
Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)28 December 2023
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager26 December 2023
Chugai’s DONQ52, a Multispecific Antibody under Development for Celiac Disease, Non-Clinical Research Results Published in Nature Communications22 December 2023
Anti-CD20 Monoclonal Antibody Rituxan® Approved for Suppression and Treatment of Antibody-mediated Rejection in Organ Transplantation21 December 2023
GSK enters exclusive license agreement with Hansoh for HS-2009321 December 2023
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint21 December 2023
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases20 December 2023
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis20 December 2023
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program20 December 2023
MBrace Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial Evaluating Investigational Antibody-Drug Conjugate MBRC-10119 December 2023
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports